Status:
UNKNOWN
Neurobiological Analyses Within the FORESEE III Study
Lead Sponsor:
University Hospital Freiburg
Collaborating Sponsors:
German Center for Neurodegenerative Diseases (DZNE)
University Medical Center Freiburg
Conditions:
Treatment Resistant Depression
Eligibility:
All Genders
20-75 years
Brief Summary
In this observational, non-invasive clinical study different neurobiological analyses will be performed in a group of patients with severe treatment resistant major depression participating in an effi...
Detailed Description
This study is a sub-project of the FORESEE III study (Controlled Randomized Clinical Trial to assess Efficacy of Deep Brain Stimulation (DBS) of the slMFB in Patients with Treatment Resistant Major De...
Eligibility Criteria
Inclusion
- DBS Patients:
- All enrolled subjects of the Controlled Randomized Clinical Trial to assess Efficacy of Deep Brain Stimulation (DBS) of the slMFB in Patients with Treatment Resistant Major Depression (FORESEE III) may participate in this study.
Exclusion
- Non-Caucasian (because of requirements for genetic/epigenetic analyses)
- Somatic diseases like diabetes, cancer and severe liver- and kidney-diseases
- Healthy Controls:
- Inclusion Criteria:
- All healthy volunteers without any clinically significant psychiatric or somatic symptoms are eligible.
Key Trial Info
Start Date :
August 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 1 2023
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT04021823
Start Date
August 1 2019
End Date
June 1 2023
Last Update
November 10 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Freiburg
Freiburg im Breisgau, Baden-Wurttemberg, Germany, 79106